Chronic Lymphocytic Leukemia
February 2018 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Chronic Lymphocytic Leukemia abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Chronic Lymphocytic Leukemia. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Chronic Lymphocytic Leukemia. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Chronic Lymphocytic Leukemia every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:SnapShot: Chronic Lymphocytic Leukemia.
Authors:Ten Hacken E, Guieze R, Wu CJ
Institution:Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA. Harvard Medical School, Boston, MA, USA; Broad Institute, Cambridge, MA, USA.
Journal:Cancer Cell. 2017 Nov 13;32(5):716-716.e1. doi: 10.1016/j.ccell.2017.10.015.

2:Therapeutics targeting Bcl-2 in hematological malignancies.
Authors:Ruefli-Brasse A, Reed JC
Institution:Roche, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel 4070, Switzerland Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel 4070, Switzerland.
Journal:Biochem J. 2017 Oct 23;474(21):3643-3657. doi: 10.1042/BCJ20170080.

3:FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.
Authors:Chai-Adisaksopha C, Brown JR
Institution:Department of Medicine and. Hamilton, ON, Canada; and. Harvard Medical School, Boston, MA.
Journal:Blood. 2017 Nov 23;130(21):2278-2282. doi: 10.1182/blood-2017-07-731588. Epub 2017 Oct 12.

4:MALT1 Inhibition Is Efficacious in Both Naive and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
Authors:Saba NS, Wong DH, Tanios G, Iyer JR, Lobelle-Rich P, Dadashian EL, Liu D, Fontan L, Flemington EK, Nichols CM, Underbayev C, Safah H, Melnick A, Wiestner A, Herman SEM
Institution:Section of Hematology and Medical Oncology, Department of Medicine, Tulane University, New Orleans, Louisiana.; Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.; Section of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.; Department of Pathology, Tulane University, New Orleans, Louisiana.
Journal:Cancer Res. 2017 Dec 15;77(24):7038-7048. doi: 10.1158/0008-5472.CAN-17-2485. Epub 2017 Oct 9.

5:Venetoclax for the treatment of chronic lymphocytic leukemia.
Authors:Gentile M, Petrungaro A, Uccello G, Vigna E, Recchia AG, Caruso N, Bossio S, De Stefano L, Palummo A, Storino F, Martino M, Morabito F
Institution:a Hematology Unit, Department of Hemato-Oncology , Ospedale Annunziata , Cosenza , Italy. , Italy. , Italy. , Italy. Aprigliano , Italy. Aprigliano , Italy. Aprigliano , Italy. Aprigliano , Italy. Aprigliano , Italy. Aprigliano , Italy.
Journal:Expert Opin Investig Drugs. 2017 Nov;26(11):1307-1316. doi: 10.1080/13543784.2017.1386173. Epub 2017 Oct 9.

6:Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.
Authors:Robak P, Robak T
Institution:a Department of Experimental Hematology , Medical University of Lodz , Lodz , Poland.
Journal:Expert Opin Investig Drugs. 2017 Nov;26(11):1249-1265. doi: 10.1080/13543784.2017.1384814. Epub 2017 Oct 3.

7:Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.
Authors:Said R, Tsimberidou AM
Institution:a Department of Oncology , University of Balamand, St. George Hospital University Medical Center , Beirut , Lebanon. Houston , TX , USA. Houston , TX , USA.
Journal:Expert Opin Biol Ther. 2017 Nov;17(11):1463-1470. doi: 10.1080/14712598.2017.1377178. Epub 2017 Sep 11.

8:New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.
Authors:Tripathi R, Lee-Verges E, Higashi M, Gimenez N, Rosich L, Lopez-Guerra M, Colomer D
Institution:a Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hematopathology Unit , Hospital Clinic, CIBERONC , Barcelona , Spain.
Journal:Expert Opin Drug Discov. 2017 Oct;12(10):1041-1052. doi: 10.1080/17460441.2017.1362387. Epub 2017 Aug 4.

9:Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.
Authors:Hansson L, Asklid A, Diels J, Eketorp-Sylvan S, Repits J, Soltoft F, Jager U, Osterborg A
Institution:Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Journal:Ann Hematol. 2017 Oct;96(10):1681-1691. doi: 10.1007/s00277-017-3061-3. Epub 2017 Jul 31.

10:Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome.
Authors:Albi E, Baldoni S, Aureli P, Dorillo E, Del Papa B, Ascani S, Di Ianni M, Falzetti F, Sportoletti P
Institution:Institute of Hematology, Centro di Ricerche Emato-Oncologiche (CREO), University of Perugia, Perugia - Italy.; Hematology Section, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila - Italy.; Institute of Pathology, Ospedale S. Maria di Terni and University of Perugia, Perugia - Italy.
Journal:Tumori. 2017 Nov 15;103(Suppl. 1):e37-e40. doi: 10.5301/tj.5000667.

11:CD11c expression in chronic lymphocytic leukemia revisited, related with complications and survival.
Authors:Umit EG, Baysal M, Durmus Y, Demir AM
Institution:Department of Hematology, Faculty of Medicine Trakya University, Edirne, Turkey. Turkey.
Journal:Int J Lab Hematol. 2017 Oct;39(5):552-556. doi: 10.1111/ijlh.12695. Epub 2017 Jun 12.

12:IGHV mutational status testing in chronic lymphocytic leukemia.
Authors:Crombie J, Davids MS
Institution:Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Massachusetts.
Journal:Am J Hematol. 2017 Dec;92(12):1393-1397. doi: 10.1002/ajh.24808. Epub 2017 Jul 29.

13:Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis.
Authors:Wu Y, Wang Y, Gu Y, Xia J, Kong X, Qian Q, Hong Y
Institution:a Medical Institution Conducting Clinical Trials for Human Used Drug, The Fifth People's Hospital of Shanghai , Fudan University , Shanghai , China.; b Department of General Psychiatry, Shanghai Mental Health Center , Shanghai Jiaotong University , Shanghai , China.; c Department of Hematology, The Fifth People's Hospital of Shanghai , Fudan University , Shanghai , China.; d Department of Osteology, The Fifth People's Hospital of Shanghai , Fudan University , Shanghai , China.
Journal:Hematology. 2017 Dec;22(10):578-584. doi: 10.1080/10245332.2017.1333974. Epub 2017 Jun 3.

14:Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.
Authors:Howard DR, Munir T, McParland L, Rawstron AC, Milligan D, Schuh A, Hockaday A, Allsup DJ, Marshall S, Duncombe AS, O'Dwyer JL, Smith AF, Longo R, Varghese A, Hillmen P
Institution:Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. University of Leeds, Leeds, UK. Leeds, UK. Birmingham, UK. Oxford University Hospital Trust, Oxford, UK. University of Leeds, Leeds, UK. Kingdom and Hull York Medical School, University of Hull, Hull, UK. of Leeds, Leeds, UK. of Leeds, Leeds, UK. of Leeds, Leeds, UK. (LICAP), University of Leeds, Leeds, UK.
Journal:Leukemia. 2017 Nov;31(11):2416-2425. doi: 10.1038/leu.2017.96. Epub 2017 Mar 24.

15:Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
Authors:Munir T, Howard DR, McParland L, Pocock C, Rawstron AC, Hockaday A, Varghese A, Hamblin M, Bloor A, Pettitt A, Fegan C, Blundell J, Gribben JG, Phillips D, Hillmen P
Institution:Department of Haematology, St James's University Hospital, Leeds, UK. University of Leeds, Leeds, UK. University of Leeds, Leeds, UK. Leeds, UK. University of Leeds, Leeds, UK. Liverpool, UK.
Journal:Leukemia. 2017 Oct;31(10):2085-2093. doi: 10.1038/leu.2017.65. Epub 2017 Apr 20.

16:Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Authors:Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM, Salem AH
Institution:Abbvie Inc., North Chicago, IL, USA.
Journal:Hematol Oncol. 2017 Dec;35(4):679-684. doi: 10.1002/hon.2373. Epub 2016 Dec 16.

17:First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.
Authors:Meunier G, Ysebaert L, Nguyen-Thi PL, Lepretre S, Quinquenel A, Dupuis J, Lemal R, Aurran T, Tomowiak C, Cymbalista F, Dilhuydy MS, Brion A, Morel P, Cazin B, Leblond V, Cartron G, Re D, Bene MC, Michallet AS, Feugier P
Institution:Nancy University Hospital, France.
Journal:Hematol Oncol. 2017 Dec;35(4):671-678. doi: 10.1002/hon.2370. Epub 2016 Nov 22.

For a FREE PREVIEW of the Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia...
at a Special 20% Discount

Medifocus Guidebook on Chronic Lymphocytic Leukemia

Updated: January 10, 2018
190 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: April 20, 2018

What Our Customers Are Saying...

"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
Coedpoeth, United Kingdom

Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.